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Background: The extent of gut microbial translocation, which plays roles in HIV disease 
progression and non-AIDS comorbidities, appears to vary with the composition of the gut 
microbiome, particularly the presence of Lactobacillales, which reduce mucosal injury. 
While low proportions of Lactobacillales in the distal gut microbiome are a very promising 
indicator of microbial translocation, measurement is expensive and complicated and not 
feasible for clinical routine. (1→3)-β-d-Glucan (BDG) is a component of most fungal cell 
walls and might be a surrogate marker for Lactobacillales proportion in the gut and a 
useful indicator of HIV-associated gut injury. This study evaluated BDG as a biomarker of 
gut integrity in adults with acute or early HIV infection (AEH).
Methods: Study samples were collected longitudinally during study visits at weeks 
0, 12, and 24 in a cohort of 11 HIV-infected men starting antiretroviral therapy during 
AEH. Blood plasma levels of BDG, soluble cluster of differentiation 14 (sCD14) and 
lipopolysaccharide (LPS) were measured and then correlated with the proportion of 
Lactobacillales in the distal gut microbiome, as measured by 16s rDNA sequencing by 
using mixed-effects models with random intercepts.
results: Mean BDG and sCD14 levels across subjects were associated with 
Lactobacillales after controlling for time effects and within-subjects correlations (p-val-
ues < 0.05), while LPS levels were not. Specifically, each point increase in mean BDG 
and sCD14 levels across participants was associated with 0.31 ± 0.14 and 0.03 ± 0.01 
percent decrease in mean Lactobacillales proportions, respectively.
conclusion: BDG and sCD14 may be indicators of low Lactobacillales in the gut in 
adults with acute or early HIV infection, and serve as biomarkers of gut integrity and 
microbial translocation in HIV infection. Larger studies are needed to confirm our findings.
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inTrODUcTiOn
CD4+ T cells trigger many elements of the immune response, 
including regulation of CD8+ T cell activation (1). Early HIV 
infection is characterized by a dramatic depletion of CD4+ T cells 
and impaired polarization of Th17 cells in the gastrointestinal 
tract and a massive expansion of activated CD8+ T cells causing 
CD8+ T cell-mediated enteropathy (2–4), which is also charac-
terized by microbial overgrowth and translocation of microbial 
products, including bacteria, fungi, and viruses, from the gut into 
the systemic circulation (5). Lactobacillales influence gut mucosal 
immunity by increasing the suppressive function of CD4+ 
regulatory T cells of colon lamina propria, which can alleviate 
HIV-associated colitis (1). High proportions of Lactobacillales in 
the distal gut microbiome appear to reduce mucosal injury, lower 
inflammatory responses, reduce barrier disruption (6, 7), and 
may result in less microbial translocation during HIV infection 
(4, 8, 9). Low proportions of Lactobacillales may, therefore, serve 
as an indicator of microbial translocation, which likely plays a role 
in HIV disease progression and non-AIDS comorbidities, even 
when antiretroviral treatment is initiated early in the course of 
infection (10–12). However, determination of gut Lactobacillales 
proportion is expensive and complicated. Surrogate markers for 
Lactobacillales proportion in the gut microbiome are, therefore, 
needed for the clinical routine.
The polysaccharide (1→3)-β-d-glucan (BDG) is a cell wall 
component of most fungal species, and is used as a serum bio-
marker for early diagnosis of invasive fungal infections (13–15). 
BDG is not highly specific for fungal infections, however, and 
among individuals with HIV infection but without invasive 
fungal infection, elevated levels of BDG in serum correlate 
with HIV-associated immunosuppression, inflammation, and 
cardiopulmonary comorbidity (16, 17). Consistent with these 
links, a recent report indicates that BDG may be a promising 
biomarker for neurocognitive impairment in virally suppressed 
HIV-infected adults (18). The pathogenic mechanism behind this 
finding remains unclear.
We hypothesized that in the absence of invasive fungal infec-
tion, BDG may be a biomarker of gut mucosal barrier disruption 
(19, 20) and microbial translocation (21), potentially contribut-
ing to HIV-associated morbidity (22). The objective of this pilot 
study was to evaluate BDG as a marker of gut permeability by 
correlating blood BDG with proportions of Lactobacillales in the 
distal gut microbiome of individuals diagnosed with acute and 
early HIV infection.
MaTerials anD MeThODs
In this longitudinal observational analysis, we retrospectively 
measured levels of BDG in blood plasma samples in a cohort of 
adults with acute and early HIV infection, and compared BDG 
levels and established biomarkers of microbial translocation with 
16s rDNA sequencing of the gut microbiome.
All 13 individuals participated in the San Diego Primary HIV 
Infection Research Consortium (SD PIRC), which is composed of 
individuals diagnosed with acute or early HIV-infection (acute: HIV 
nucleic acid amplification testing+/antibody- consistent with 
infection <30 days; early: HIV antibody+/detuned HIV Ab con-
sistent with infection <70 days) followed longitudinally (23–25). 
The UCSD Human Research Protections Program approved the 
study protocol, consent document, and all study procedures. All 
participants provided voluntary, written informed consent. All 
participants started ART within 2 weeks of study enrollment with 
a combination of tenofovir, emtricitabine, and ritonavir-boosted 
atazanavir, with or without maraviroc according to a randomiza-
tion schedule at entry (baseline). Paired anal swabs [anal swabs 
have been shown to produce highly reproducible microbiota 
profiles resembling the human gut microbiota (26)] and blood 
samples were collected sequentially during study visits at baseline 
and at weeks 12 (±2 weeks) and 24 (±6 weeks) between August 
2010 and September 2011 at the University of California, San 
Diego and stored at −80°C on the day of collection (4).
(1→3)-β-d-glucan was measured by the Fungitell assay in June 
2015 at the Associates of Cape Cod, Inc., research laboratories 
(Associates of Cape Cod, Inc, East Falmouth, MA, USA). Both 
comparator biomarkers were measured in 2012 and have been – 
in part – published before (4). Soluble cluster of differentiation 
14 (sCD14) was measured by immunoassay (Quantikine, R&D 
Systems, Minneapolis, MN, USA). Lipopolysaccharide (LPS) was 
measured by the Limulus Amebocyte Lysate QCL-1000 assay.
DNA extractions from anal swabs were performed in 2012 
using the QIAamp Stool DNA kit (Qiagen) (4). Amplification 
of bacterial DNA and pyrosequencing amplification of the V6 
hypervariable region of the 16 S rDNA gene was carried out in a 
50 μl reaction using the highly purified Amplitaq Gold Low DNA 
polymerase (Applied Biosystems, Foster City, CA, USA) (4). For 
classification of bacteria, we kept bacterial sequences with at least 
90 continuous base pairs with a quality score of at least 20 for 
further analyses as described before (4).
Statistical analyses were performed using SPSS 22 (SPSS Inc., 
Chicago, IL, USA). As study samples were collected longitudinally 
(i.e., repeated measures) we applied mixed-effects models with 
random intercepts to test whether Lactobacillales proportions 
were associated with between-subjects (Bw) as well as within-
subjects (Wi) BDG levels after adjustment for repeated measures. 
The same analysis was repeated for other biomarkers (sCD14, 
LPS, and CD4+ T cell counts). We used mixed-effects models to 
analyze our repeated-measures data because its maximum-like-
lihood estimation of the missing values allows for retaining the 
participants with missing values. In addition, the mixed-effects 
model approach increases power to detect effects and allows for a 
more accurate estimate of correlations. In addition, we also calcu-
lated cross-sectional correlations between BDG, Lactobacillales 
and other biomarkers using Pearson correlation coefficient for 
weeks 12 and 24 and Spearman correlation coefficient for baseline 
due to skewed distributions at week 0 (i.e., secondary analysis). 
resUlTs
Thirteen men diagnosed with acute (8/13) or early (5/13) HIV 
infection enrolled. Median age was 29 years (range 21–55 years). 
About a third (4/13) reported Hispanic ethnicity, the rest report-
ing White (7/13) or Asian race (2/13). Eleven of the 13 men 
completed their 12- and 24-week visits. All 11 initiated ART 
TaBle 1 | levels of plasma beta d-glucan (BDg) and cross-sectional correlations with other biomarkers, viral loads, and Lactobacillales proportions of 
distal gut bacterial flora (median and range are displayed) at baseline, week 12, and week 24.
Biomarkers Baseline (n = 13) Week 12 (n = 11) Week 24 (n = 11)
results  
[median (range)]
spearman 
correlation  
with BDg
p-Value results  
[median (range)]
Pearson 
correlation  
with BDg
p-value results  
[median (range)]
Pearson 
correlation 
with BDg
p-value
BDG (pg/mL) 39 (13–96) – – 45 (3–122) – 35 (3–89)
LPS (pg/mL) 0.358 (0.278–0.409) 0.275 n.s. 0.306 (0.278–0.393) 0.263 n.s. 0.311 (0.183–0.411) −0.241 n.s.
sCD14 (ng/mL) 1,084 (706–2,683) 0.363 n.s 1,290 (728–1,844) 0.352 n.s. 981 (858–1,493) −0.192 n.s.
CD4+ cell count 
(cells/μL)
520 (91–971) −0.126 n.s. 822 (245–1,408) −0.363 n.s. 793 (262–1,150) −0.456 n.s.
CD8+ cell count 
(cells/μL)
856 (558–5,216) −0.357 n.s. 813 (436–2,196) 0.044 n.s. 774 (588–1,906) −0.009 n.s.
CD4/CD8 ratio 0.576 (0.101–1.279) −0.055 n.s. 1.077 (0.267–1.372) −0.475 n.s. 0.888 (0.382–1.070) −0.493 n.s.
Viral loads (log10 RNA) 5.25 (3.10–7.00) 0.055 n.s. 1.914 (1.623–4.153) 0.147 n.s. 1.681 (1.681–2.702) 0.113 n.s.
Lactobacillales (%) 41.49 (5.15-52.12; n = 11) −0.109 n.s. 26.40 (6.16–41.68) −0.639 0.034 22.85 (3.04–47.94) −0.542 0.085
FigUre 1 | cross-sectional associations between levels of beta-d-glucan and proportions of Lactobacillales in the distal gut (a) at week 12 (B) at 
week 24 of follow up in individuals with acute or early hiV infection.
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between baseline and week 12, 5/11 (45%) achieving viral sup-
pression (i.e. <50 copies/mL) by week 12, and 8/11 (73%) by week 
24. Participants who were not virally suppressed (i.e., HIV RNA 
>50 copies/mL) at week 12 (6/11) showed a trend for higher BDG 
levels in plasma (median 52 pg/mL, range 12–122 pg/mL) when 
compared to those who were virally suppressed (median 9 pg/
mL, range 3–46 pg/mL; p = 0.052, Mann–Whitney U test), while 
there was no difference at week 24. In addition, no difference in 
the levels of BDG was observed between participants with and 
without maraviroc (n =  7; median 39, range 13–96 vs. n =  6; 
median 39, range 20–89; p > 0.20 at all timepoints). At baseline, 
BDG levels did not differ between participants with early HIV 
infection (median 63 pg/mL, range 13–89 pg/mL) and those with 
acute HIV infection (median 37 pg/mL, range 20–96 pg/mL).
Levels of clinical and immunological variables as well as the 
correlation analyses for each time point separately are depicted 
in Table 1. The median proportion of Lactobacillales in the distal 
gut was 41.5% [range 5.2–52.1%; n =  11 (two individuals who 
received systemic antibacterial therapy were excluded)] at base-
line, 26.4% (range 6.2–41.7%; n = 11) at week 12, and 22.8% (range 
3.0–47.9%) at week 24. While in cross-sectional analysis, there 
was no correlation between levels of BDG and Lactobacillales at 
baseline, there was a negative correlation at week 12 and a trend 
at week 24. Scatter plots showing correlations of blood BDG 
levels and proportions of Lactobacillales at weeks 12 and 24 are 
displayed in Figure 1.
In the mixed-effects model, higher proportions of Lactobacillales 
were associated with lower Bw BDG (p =  0.023, Table  2) and 
FigUre 2 | longitudinal associations of BDg, lPs, and scD14 with proportions of Lactobacillales proportion in the distal gut. Big dots indicate mean 
levels for each subject, and small dots indicate individual observations. Black lines indicate linear regression lines fitted to the mean values, while gray lines indicate 
non-linear smooth lines.
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lower Bw sCD14 (p =  0.035). Specifically, each point increase 
in mean BDG and sCD14 levels across participants were associ-
ated with 0.31 ± 0.14 and 0.03 ± 0.01 percent decrease in mean 
Lactobacillales proportions, respectively. These two predictors 
(BDG and sCD 14) were highly correlated (r = 0.69, p = 0.01). 
Lactobacillales was not associated with Bw LPS (p > 0.2) nor with 
Bw CD4+ cell count (p = 0.095). None of the time or Wi effects 
showed significant associations (p-values > 0.2). Scatter plots of 
mean Wi BDG, LPS, and sCD14 levels predicting Lactobacillales 
proportion in the distal gut are displayed in Figure  2. The big 
dots are means across longitudinal observations, representing 
more stable estimates of predictor levels and proportions of 
Lactobacillales. The regression lines fit to those means and, 
therefore, represent stable estimates of correlations. The small 
dots indicate individual observations.
DiscUssiOn
This is the first study to evaluate blood levels of the fungal 
polysaccharide BDG in individuals with acute or early HIV 
infection. We found that higher levels of blood BDG cor-
related with higher levels of sCD14 and lower proportions 
of gut Lactobacillales. High proportions of Lactobacillales in 
the distal gut microbiome have been shown to reduce barrier 
disruption (6, 7), and result in less microbial translocation 
during HIV infection (4, 8, 9), even when administered as a 
probiotic treatment (27). Correlation of BDG with high levels 
of sCD14 and low proportions of Lactobacillales may, there-
fore, suggest that BDG may be a biomarker of gut integrity 
and microbial translocation in individuals with acute or early 
HIV infection.
TaBle 2 | summary of mixed-effects models for BDg and other biomarkers predicting Lactobacillales proportions.
BDg lPs scD14 cD4+ cell count
β sMD β sMD β sMD β sMD
(Intercept) 30.47 (4.05)*** 3.5 31.04 (4.57)*** 3.3 31.91 (4.11)*** 3.7 31.12 (4.48)*** 3.3
Time −0.19 (0.23) 0.4 −0.26 (0.25) 0.5 −0.29 (0.23) 0.6 −0.22 (0.27) 0.4
Bw −0.31 (0.14)* 1.4 −29.03 (79.42) 0.2 −0.03 (0.01)* 1.3 0.02 (0.01)† 1.0
Wi 0.05 (0.13) 0.2 −5.61 (86.71) 0.0 −0.01 (0.01) 0.5 0.00 (0.02) 0.0
Bw, between-subjects effect; Wi, within-subjects effect, SMD, standardized mean difference effect-size measure (>0.8 = large effect). Bw and Wi are centered at the grand mean 
and subject means, respectively. The value inside the parentheses indicates the SE for β. †p < 0.10, *p < 0.05, ***p < 0.001 based on likelihood-ratio tests.
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Our findings may have important clinical implications, as 
microbial translocation may be a major contributing factor to 
HIV-associated morbidity (22, 28). Two previous studies found 
that blood BDG levels correlated directly with non-AIDS comor-
bidities among individuals with chronic HIV infection. Morris 
and colleagues found that high blood BDG was associated with 
HIV-associated immunosuppression, inflammation (plasma 
interleukin-8 and tumor necrosis factor-α), and cardiopulmonary 
comorbidity in 132 HIV-infected outpatients, the majority of 
whom had measurable HIV RNA in their blood (17). Our study 
team recently reported that higher blood BDG levels correlated 
with worse neurocognitive performance in 19 virologically sup-
pressed HIV-infected adults (18). While both studies explained 
their findings with the hypothesis that elevated plasma BDG may 
primarily reflect translocation of products from endogenous fun-
gal flora from the gastrointestinal tract into systemic circulation, 
this is the first study that actually evaluated BDG as a biomarker 
of the composition of the gut microbiome, namely Lactobacillales 
(4, 6–8, 22, 29, 30).
In this study, the mean levels of BDG and sCD14 across 
subjects correlated strongly and were significantly associated 
with Lactobacillales after controlling for time effects and within-
subjects correlations, while no significant correlations were 
found between LPS and Lactobacillales. The lack of associations 
of LPS with other biomarkers of microbial translocation may be 
explained by the fact that currently available LPS assays rely on 
limulus amebocyte lysate (LAL) reagents, which are not specific 
for endotoxin and may be subject to cross-reactivity (31, 32).
Our results indicate that BDG correlates with sCD14 and may 
be an indicator of low Lactobacillales in the gut and increased 
microbial translocation in adults with acute or early HIV infec-
tion. This theory is supported by a number of studies reporting 
positive BDG levels during hemodialysis (33, 34), most likely 
explained by transient reduced blood flow within the splanchnic 
region (35), potentially resulting in ischemia and a transient 
barrier damage in the gut. By contrast, another recent study did 
not find elevated serum BDG levels in hematological malignancy 
patients suffering for mild to moderate mucositis (36).
We also observed a trend toward higher BDG levels in those 
who were not virologically suppressed at week 12. This finding is 
in line with results from Morris and colleagues who found that 
high BDG levels were associated with high viral loads and also 
low CD4+ cell counts among chronically infected individuals 
(17). While elevated blood BDG levels may be associated with 
microbial translocation in all HIV-infected individuals (i.e., 
independent of CD4+ cell counts), interpretation of elevated 
blood BDG levels in individuals with CD4+ cell counts below 
200–300  cells/μL may be more complicated. While it seems 
intuitive that deteriorating CD4+ counts are associated with 
worse mucosal barrier function (21), other reasons for elevated 
BDG may include potential colonization or subclinical infection 
with Candida spp. or Pneumocystis (15) that may occur more 
frequently in individuals with lower CD4 counts.
Major limitations of this small study include its small sam-
ple size, its cross-sectional, single-site design, and its focus on 
adults with acute or early HIV infection. While the mechanistic 
hypothesis of the correlation between Lactobacillales proportion 
in the gut and microbial translocation has been evaluated in a 
number of studies, very few studies to date have actually reported 
that the proportion of Lactobacillales may be an indicator of 
microbial translocation, and the most important study showing 
this correlation used in part the same samples that were used in 
this study. Also BDG has been primarily used as a biomarker for 
fungal infection and BDG cut-off levels for microbial transloca-
tion have yet not been defined. However, our study cohort of 
individuals with AEH presented with markedly higher BDG 
levels when compared to previously published levels from healthy 
individuals undergoing elective plastic surgery procedures 
(37). In addition, cross-sectional analyses of this longitudinal 
data were limited by particularly small sample sizes. Another 
explanation for the absence of correlation between BDG levels 
and Lactobacillales in cross-sectional analysis at baseline may be 
the fact that Lactobacillales proportions were markedly lower at 
week 12 and week 24 of follow-up when compared to baseline 
(median 22–26% vs. median 41%). The clear negative correlations 
between BDG and Lactobacillales and positive correlations with 
sCD14 levels in the mixed-effects model suggest nevertheless that 
BDG may be an indicator of gut mucosal barrier interruption and 
microbial translocation. To further examine the role of BDG as 
a potential biomarker for translocation of gut luminal contents, 
more comprehensive studies will be necessary. BDG levels in the 
intestinal luminal contents are also likely to be highly variable 
on an individual basis, and a standardized oral BDG challenge 
approach may be more suitable for assessing gut integrity.
In conclusion, high BDG levels may be a useful indicator 
of low Lactobacillales in the gut and microbial translocation in 
individuals with acute and early HIV infection. These findings 
indicate that BDG may be a promising marker for gut integrity. 
Larger studies are needed to confirm our findings.
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